» Articles » PMID: 18058265

Differential Expression of MiRNAs in Papillary Thyroid Carcinoma Compared to Multinodular Goiter Using Formalin Fixed Paraffin Embedded Tissues

Overview
Journal Endocr Pathol
Specialties Endocrinology
Pathology
Date 2007 Dec 7
PMID 18058265
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

microRNAs (miRNAs) are approximately 22 nt RNAs that negatively regulate target gene expression. Their dysregulation has been implicated in the pathogenesis of a number of human cancers, including papillary thyroid carcinoma (PTC). Whereas previous studies using microarray technologies have largely relied on the ability to procure fresh tissue at the time of surgery to characterize miRNA signatures in PTC, we exploited the ability to procure sufficient miRNA from formalin-fixed paraffin-embedded (FFPE) tissue to describe a series of miRNAs whose expression is dysregulated in PTC compared to benign proliferative multinodular goiter (MNG). We identified 13 miRNAs upregulated and 26 miRNAs downregulated in PTC versus MNG. These include miRNA-21, miRNA-31, miRNA-221, and miRNA-222. Their dysregulation was further validated by real time RT-PCR analysis in an independent set of FFPE tissues. Many of these have previously been described in fresh tissue studies as altered in PTC, confirming the utility of this approach. These results further highlight the applicability of miRNA expression patterns as potential markers of human cancer, and our results suggest that FFPE tissues are suitable resources for such miRNA expression analyses. The ability to utilize FFPE tissue in the molecular characterization of human malignancy will unlock a rich resource for future cancer studies.

Citing Articles

The Implications for Clinical Practice of Circulating miR144-3p and miR190a-5p as Promising Diagnostic Biomarkers for Thyroid Nodule Differentiation.

Hassan B, Omran M, Youssef M, Refaat M, Abouzid A, Abdel Wahab A Technol Cancer Res Treat. 2024; 23:15330338241291637.

PMID: 39703128 PMC: 11662322. DOI: 10.1177/15330338241291637.


Research on the expression of Mir-218-2 in the serum of patients with papillary thyroid cancer and its clinical significance.

He H, Hao D, Tian L, Zhu C, Guo L, Zhang K Eur J Transl Myol. 2024; 34(3).

PMID: 39221591 PMC: 11487670. DOI: 10.4081/ejtm.2024.12678.


Trials and Tribulations of MicroRNA Therapeutics.

Seyhan A Int J Mol Sci. 2024; 25(3).

PMID: 38338746 PMC: 10855871. DOI: 10.3390/ijms25031469.


MiR-20b Tissue Expression Level Displays the Diagnostic Value in Papillary Thyroid Carcinoma.

Honardoost M, Maghsoomi Z, Karimi Behnagh A, Nazanin Hosseinkhan , Abdolmaleki F, Panahi M Med J Islam Repub Iran. 2023; 37:101.

PMID: 38021380 PMC: 10657271. DOI: 10.47176/mjiri.37.101.


New biomarkers: prospect for diagnosis and monitoring of thyroid disease.

Macvanin M, Gluvic Z, Zaric B, Essack M, Gao X, Isenovic E Front Endocrinol (Lausanne). 2023; 14:1218320.

PMID: 37547301 PMC: 10401601. DOI: 10.3389/fendo.2023.1218320.


References
1.
He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

2.
Cinti R, Yin L, Ilc K, Berger N, Basolo F, Cuccato S . RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet Cell Genet. 2000; 88(1-2):56-61. DOI: 10.1159/000015485. View

3.
Ciafre S, Galardi S, Mangiola A, Ferracin M, Liu C, Sabatino G . Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334(4):1351-8. DOI: 10.1016/j.bbrc.2005.07.030. View

4.
Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

5.
Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y . BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003; 22(41):6455-7. DOI: 10.1038/sj.onc.1206739. View